bioihbjkbjnl/mcl2 huggingface dataset:
A Comparison of Management Strategies of Asthma in Pregnancy
Condition: Asthma; Pregnancy
MeSH terms: Asthma
Study type: Observational

Summary: 
      Investigate differences in practice patterns in providers who may care for pregnant women
      with asthma exacerbations. The investigators believe that practitioners of different
      specialties will practice differently.
    

Detailed description: 
      The goal of this investigation is to determine how physicians manage pregnant patients with
      asthma exacerbations using patient vignettes. Vignettes or case studies have been shown in
      various areas of medicine to be an effective tool for surveying provider's knowledge and
      application of evidence-based guidelines (9,10,11,12). Specifically, we plan on surveying
      physicians-in-training and attending physicians in Emergency Medicine, Family Medicine,
      Internal Medicine, Obstetrics/Gynecology, and Pulmonary/Critical Care Medicine at the Ohio
      State University Werner Medical Center via electronic mail. Electronic mail addresses will be
      obtained from each Department or Division's Training Program Director. We have presented
      multiple, fictional, case-based scenarios and short, multiple-choice questions where the
      responder indicates how they would manage the case. No existing patient data will be used in
      the scenarios. In addition, demographic data of the physician including length of time in
      practice, numbers of patients seen with asthma exacerbations per month, and comfort level
      with the National Asthma Education and Prevention Program Guidelines (1). The survey is
      attached. Physicians who do not respond to the first electronic mail will be sent one
      follow-up electronic mail with a second request to complete the survey. Results from the
      questionnaires completed by each department/devision of physicians will be compared and
      analyzed for significant differences. The results will then be used to look for educational
      opportunities to improve the care of pregnant patients with asthma exacerbations.
    

Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Physicians-in-training and attending physicians in Emergency Medicine, Family Medicine,
        Internal Medicine, Obstetrics/Gynecology, and Pulmonary/Critical Care Medicine at the Ohio
        State University Werner Medical Center
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Condition: Parkinson's Disease
MeSH terms: Parkinson Disease
Study type: Interventional
Phase: Phase 3

Summary: 
      Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an
      estimated incidence of 4.5-16/100,000 persons/year.

      BIA 9-1067 is currently being developed by BIAL (Portela & Cª,S.A.) to be used in addition to
      L-DOPA (Levodopa) /carbidopa or L-DOPA (Levodopa) / preparations in PD patients. Promising
      results have been obtained for BIA 9-1067 in previous studies.
    

Detailed description: 
      This study aims to demonstrate the efficacy and safety of BIA 9-1067 used in addition to
      L-DOPA/DDCI to control the "wearing-off" phenomenon in patients with PD.

      DDCI (DOPA decarboxylase inhibitors): benserazide and carbidopa
    

Intervention name(s): BIA 9-1067; Placebo; Levodopa; Carbidopa; Benserazide
Intervention type(s): Drug; Drug; Drug; Drug; Drug
Intervention description(s): Capsules will be used.; comparator; DOPA decarboxylase inhibitor (DDCI); DOPA decarboxylase inhibitor
Other intervention name(s): Opicapone; placebo; PLC; L-Dopa
Intervention MeSH terms: Levodopa; Carbidopa; Opicapone; Benserazide
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Parkinson; PD; Wearing-off; Levodopa/DDCI
A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants
Condition: Healthy Volunteers
Study type: Interventional
Phase: Phase 1

Summary: 
      The main purpose of this study is to investigate how the body responds to evacetrapib and to
      evaluate the safety and the effect of evacetrapib, alone and in combination with selected
      statins, in healthy Chinese participants. The study has 2 parts. Part one will last up to 4
      weeks and part two will last up to 5 weeks, not including screening. Participants may only
      enroll in one part.
    


Intervention name(s): Evacetrapib; Simvastatin; Atorvastatin
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Administered orally.; Administered orally.; Administered orally.
Other intervention name(s): LY2484595
Intervention MeSH terms: Atorvastatin; Simvastatin; Evacetrapib
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Basic Science
Acceptability and Tolerance of a Protein and Micronutrient Fortified Food
Condition: Poor Nutrition
MeSH terms: Malnutrition
Study type: Interventional

Summary: 
      Acceptability and tolerance of a new food product in adults and children.
    

Detailed description: 
      Acceptability and tolerance testing will be conducted in 10 healthy male adult volunteers and
      10 (40 - 60 years of age), and in children (9-13 years of age). All participants will be
      asked to consume 50g of a test product every day for 2 weeks for the adult volunteers, while
      the children will be asked to consume the same product every day for one week. The
      participants will record amount of daily intake, and will be given an entry and exit surveys.
      These surveys will include the assessment of potential gastrointestinal changes with daily
      product intake, and will include questions on how they liked the product. Acceptability will
      be measured as the number of servings and portion of serving completed each day over the
      trial period.

      In adults only, fasting blood samples and a spot urine will be collected towards preliminary
      work on potential changes in the metabolome and lipidome with the inclusion of the test
      product within the habitual diet.
    

Intervention name(s): Food Product 1
Intervention type(s): Other
Intervention description(s): 50 grams of fortified nutritious product from legumes
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Intervention model description: Single arm not blind
Masking: None (Open Label)
Primary purpose: Other
Efficacy Study of Acupuncture to Relieve Symptoms of Chronic Prostatitis
Condition: Prostatitis
MeSH terms: Prostatitis
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      Limited evidence suggests that acupuncture may help relieve symptoms of chronic
      prostatitis/chronic pelvic pain syndrome. This study evaluated if acupuncture twice weekly
      for 10 weeks would help ameliorate symptoms of CP/CPPS.
    

Detailed description: 
      Various studies have reported that this acupuncture able to relieve symptoms of chronic
      prostatitis (CP)/ chronic pelvic pain syndrome (CPPS). However, controversy exists on the
      efficacy of this technique due to poor experimental designs and lack of placebo controls in
      these experiment. This study is the first randomised controlled study which will evaluate if
      acupuncture for 10 weeks will help improve symptoms of CP/CPPS
    

Intervention name(s): Acupuncture
Intervention type(s): Procedure
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
Keywords: Prostatitis
Ultrasound Guided Axillary Brachial Plexus Block Versus Supraclavicular Block in Emergency Crushed Hand Patients
Condition: the Study Focuses on Comparing Between Supraclavicular and Axillary Blocks
MeSH terms: Emergencies
Study type: Interventional

Summary: 
      The current study focused on ultrasound guided brachial plexus block (BPB) which plays an
      important role in patients with hand trauma either in pain control or for surgical
      intervention. The brachial plexus can be blocked by several techniques but the most commonly
      used are the supraclavicular (SCB) and axillary (AXB) blocks. Aim of this study is to compare
      between the two techniques as regard performance time, needling time, anesthesia related
      time, block related complications, number of needle pass, and block related pain. 80 patients
      were allocated randomly into two equal groups, under ultrasound guidance the SCB and AXB were
      done for the two groups respectively. The needling time, performance time, anesthesia related
      time, onset time, number of 1st needle pass in each group and block related complications
      were noted.
    


Intervention name(s): brachial plexus block
Intervention type(s): Procedure
Other intervention name(s): nerve block
Allocation: Randomized
Intervention model: Parallel Assignment
Primary purpose: Other
Retrospective Evaluation of Combination Treatment With the Ulthera System
Condition: Skin Laxity
MeSH terms: Cutis Laxa
Study type: Observational

Summary: 
      A retrospective study to evaluate the Ulthera® System for its potential interaction with
      toxins and fillers. Up to 500 subjects will be enrolled.
    

Detailed description: 
      This is a retrospective, multi-site study involving chart reviews of subjects who have
      received an Ultherapy treatment along with Radiesse®, Xeomin®, and/or Belotero® Balance
      within six months apart in the face and/or neck areas. Enrolled subjects will have received
      an Ultherapy treatment along with botulinum toxin A and/or filler treatment(s) within the
      last two years and with filler and toxin treatment occurring within 6 months before or after
      Ultherapy.
    

Intervention name(s): Ultherapy; Incobotulinumtoxin A; Radiesse; Belotero Balance
Intervention type(s): Device; Drug; Device; Device
Intervention description(s): Focused ultrasound energy delivered below the surface of the skin.; An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.; An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).; An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).
Other intervention name(s): Ulthera System Treatment; Xeomin; Volumizing filler; Dermal filler
Intervention MeSH terms: Hyaluronic Acid
Observational model: Cohort
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        Adults between 25 and 70 years of age who have received an Ultherapy treatment and
        toxin/filler within the last two years within six months apart and meet the
        inclusion/exclusion criteria.
Clinical Outcome Comparison Between Medial and Lateral Offset Reverse Shoulder Arthroplasty
Condition: Rotator Cuff Tear; Proximal Humerus Fractures; Malunions; Chronic Proximal Humerus Dislocations
MeSH terms: Rotator Cuff Injuries; Humeral Fractures
Study type: Observational

Summary: 
      The purpose of this study is to prospectively evaluate two FDA approved implant designs for
      the Tornier Reverse Shoulder arthroplasty. The small difference in design is the amount of
      offset each implant has. This offset may improve clinical outcomes in the patient population.
      There have been no clinical comparative studies between these two designs in the literature
      to date. We would like to follow these patients for two years after implantation of the
      reverse shoulder and evaluate their radiographs, pain scores, and shoulder functional scores.
      this would be the first randomized prospective single blinded study of its kind.
    

Detailed description: 
      The combination of shoulder arthritis and rotator cuff deficiency presents quite a surgical
      challenge. The reverse prosthesis offers a treatment option for subset of patients as
      previous attempts to treat with soft tissue reconstruction or conventional arthroplasty have
      provided sub-optimal clinical results. Numerous reports in the literature have validated the
      effectiveness of the reverse design.

      Patients meeting criteria must be between the ages of 50 and 95 years of age and are a
      candidate for a reverse shoulder arthroplasty. This is includes patients with rotator cuff
      tear arthroplasty, irreparable rotator cuff tears, significant proximal humerus fractures and
      malunions, and chronic proximal humerus dislocators. A total of 40 patients will be enrolled
      and randomized to either one of two groups; 20 patients will be randomized to the Tornier
      Reversed shoulder Arthroplasty Medial offset, and 20 will receive the Lateral offset design.
      Both implants are FDA approved. The patients will be followed for 24 months and will
      follow-up will be at 6 weeks, 3 months, 6 months, 12 months and 24 months questionnaires will
      be completed at each visit, x-rays will be done at pre-op, 3 month, 6 months 12 and 24
      months.
    

Observational model: Case-Only
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Elderly/aged, Inpatient and outpatient, healthy patients, females, males physically
        handicapped, Seventh-day Adventist cohort.
      
Keywords: irreparable rotator cuff tears
SZMN Blocks for Pain Control in Pediatric Patients Undergoing T&A
Condition: Postoperative Pain; Opioid Use
MeSH terms: Pain, Postoperative
Study type: Interventional

Summary: 
      The suprazygomatic maxillary nerve (SZMN) block is a well-established, safe and effective
      regional technique for pain management following cleft palate procedures, however, have not
      been studied for patients undergoing tonsillectomy and adenoidectomy (T&A) procedures. The
      goals of this study are to determine if SZMN block can be utilized for pain control and
      decrease morbidity in pediatric patients undergoing T&A.
    

Detailed description: 
      Patients between 6 months and 18 years undergoing T&A surgical procedures will be reviewed
      for potential study enrollment. If participants agree to participate, they will be randomized
      into either the suprazygomatic maxillary nerve (SZMN) block treatment cohort or the control
      cohort i.e standard of care.

      After anesthesia induction, patients randomized into the SZMN- treatment group will receive a
      bilateral single injection SZMN block under general anesthesia in the operating room. The
      injection will occur near the temples above the cheek bones.

      Participants enrolled into the control group will receive standard of care with no changes to
      their anesthetic or surgical care. Both groups will be asked for their verbal pain scores in
      the PACU and we will track their opioid consumption throughout the next few days after their
      procedure.
    

Intervention name(s): SZMN Block
Intervention type(s): Procedure
Intervention description(s): Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally near the temples of the patient
Allocation: Randomized
Intervention model: Single Group Assignment
Intervention model description: Patients in the interventional group will receive a total of 5 mL of local anesthetic bilaterally near their temples.
Masking: Double (Participant, Care Provider)
Primary purpose: Treatment
Keywords: SZMN Block; Tonsillectomy and Adenoidectomy; Regional Anesthesia
the Safety and Efficacy of Meplazumab in Patients With COVID-19
Condition: Covid19
MeSH terms: COVID-19
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      This is a multicenter, double-blind, randomized, placebo-controlled phase 2/3 clinical study.
      Based on the results of the Phase I clinical study, one repeat dose group and one placebo
      group are used for the standard treatment of the Novel Coronavirus Pneumonia Protocol (Trial
      8) The treatment regimen is a one-time intravenous infusion of either mprozumab or placebo on
      day 1 (D1) and day 8 (D8) of the treatment period at a dose of 0.2 mg/kg based on body
      weight. An estimated 150 subjects will be randomly assigned to either Meplazumab or placebo
      in a 2:1 ratio A short-term efficacy evaluation was performed to determine the efficacy and
      safety of Meplazumab in each subject within 14 days of initial administration and a long-term
      follow-up evaluation was performed 28 days after initial administration to determine the
      safety of Meplazumab.
    


Intervention name(s): Meplazumab for Injection; Sterile normal saline (0.9%)
Intervention type(s): Drug; Drug
Intervention description(s): humanized antibody target CD147; Sterile normal saline (0.9%)
Intervention MeSH terms: Meplazumab
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Luteal Phase-start Ovarian Stimulation With Corifollitropin Alfa
Condition: Infertility
MeSH terms: Infertility
Study type: Interventional

Summary: 
      To evaluate the effect of random-start of ovarian stimulation initiated in the early
      follicular or luteal phase on the pharmacokinetics and follicular dynamics and embryo
      euploidy rates in oocyte donors treated with identical ovarian stimulation protocols with
      corifollitropin alfa and GnRH antagonist pituitary downregulation
    

Detailed description: 
      The scope of the current prospective trial is to investigate whether Luteal Stimulation (LS)
      results in equivalent euploid embryos with Follicular Stimulation (FS) in young reproductive
      age women. The use of the "oocyte donor model" allows extrapolation of the results and
      application of LS routinely not only in healthy women undergoing fertility preservation but
      also in all patients irrespective of the menstrual date. This may indeed allow widespread
      introduction of LS in IVF programs which may result in proper scheduling of ovarian
      stimulation which is a major issue in everyday clinical practice.

      Given that the pharmacokinetics and follicular dynamics of 150μg corifollitropin alfa for
      luteal stimulation has never been evaluated, the current study of luteal stimulation with
      corifollitropin alfa could be very interesting for several reasons:

        1. Potentially immediate synchronization of oocyte donors with recipients aiming to fresh
           oocyte donation.

        2. Fertility preservation patients for medical, oncological and non-medical indication

        3. Any situation in which endometrial receptivity is not pursued.
    

Intervention name(s): Follicular phase corifollitropin alfa; Luteal phase corifollitropin alfa
Intervention type(s): Drug; Drug
Intervention description(s): GnRH antagonist protocol with corifollitropin alfa initiated in the follicular phase (day 2 or 3 of the menstrual cycle); GnRH antagonist protocol with corifollitropin alfa initiated in the luteal phase (5 days after an LH peak)
Allocation: Non-Randomized
Intervention model: Sequential Assignment
Intervention model description: Overall, 44 oocyte donors women will be asked to participate in a trial in which they will undergo 2 consecutive ovarian stimulation protocols within a period of 6 months with 150μg corifollitropin alfa followed by 200 IU rFSH in a fixed GnRH antagonist protocol starting in the early follicular, and luteal menstrual cycle phase
Masking: None (Open Label)
Primary purpose: Treatment
Comparison of the Efficacy of Comprehensive Respiratory Physiotherapy in Children With Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis
Condition: Cystic Fibrosis; Bronchiectasis
MeSH terms: Cystic Fibrosis; Bronchiectasis; Fibrosis
Study type: Interventional

Summary: 
      The effect of comprehensive respiratory physiotherapy applications on respiratory function,
      functional capacity and peripheral muscle strength in children with cystic fibrosis and
      non-cystic fibrosis will be compared.
    

Detailed description: 
      Bronchiectasis may be a congenital cause such as cystic fibrosis (CF) or non-cystic fibrosis
      such as primary ciliary dyskinesia, post-infectious conditions, aspiration and
      immunodeficiency; It is a disease characterized by irreversible dilatation of airways.
      Symptoms; purulent sputum production, chronic cough, hemoptysis, recurrent fever and
      pleurisy. Mucociliary clearance disorder secondary to inflammation and involvement of
      exocrine glands in CF plays a major role in the development of symptoms; In non-cystic
      fibrosis bronchiectasis (NCFB), the development of similar symptoms may occur regardless of
      these reasons. However, in the examinations of CF, proximal airways; In NCFB, distal airways
      have been affected more intensively. As part of pulmonary rehabilitation, comprehensive
      respiratory physiotherapy (CRP) has an important role in the treatment and management of
      bronchiectasis. Airway cleaning techniques, approaches to reducing respiratory work, and
      patient education form the basis of CRP and play an active role in the treatment and
      management of the disease. In the literature, there are studies in which the effects of CRP
      are given in both CF and NCFB patients and studies comparing evaluation results in both
      groups without treatment. However, no study was found to compare the efficacy of CRP in these
      two groups of diseases. Therefore, in this study, the investigators aimed to investigate the
      differences between the efficacy of CRP among the groups in children with CF and NCFB.
    

Intervention name(s): Comprehensive Respiratory Physiotherapy
Intervention type(s): Other
Intervention description(s): All patients will receive comprehensive respiratory physiotherapy training by the physiotherapist. All patients will undergo comprehensive respiratory physiotherapy techniques twice daily for 8 weeks.
Comprehensive respiratory physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Cystic Fibrosis; Bronchiectasis; Respiratory Physiotherapy; Pulmonary Function; Exercise Capacity; Six Minute Walk Test; Muscle Strength